PharmaNest will showcase Eight Digital Pathology and AI
PRINCETON, NJ, June 20, 2022 (GLOBE NEWSWIRE) — PharmaNest, an emerging leader in quantitative digital pathology and artificial intelligence, today announces that it will present, along with its collaborators, eight presentations at the International Congress Liver (ILC) in London, June 22-25, 2022. Abstracts highlight the utility and performance of FibroNest, the first multi-vendor digital pathology translational and quantitative image analysis platform for the assessment of fibrosis severity and progression and disease activity in NASH.
“Automated quantification of the fibrosis severity phenotype from the same slides examined by pathologists offers a robust and scalable method to generate continuous scores with a detection threshold capable of detecting small changes and drug effects”, said Mathieu Petitjean, CEO and founder of Pharmanest. Because the approach is fully quantitative and not based on existing staging or grading paradigms, it can be used throughout the drug discovery and development process, and across fibrosis etiologies.
The first abstract is a retrospective analysis of liver biopsies from the Phase 2 ARMOR trial of aramchol. It shows how the Fibronest Continuous Fibrosis Score detects drug effects that are missed by conventional histological methods (in partnership with Galmed Pharmaceuticals).
A second abstract includes results from a prospective analysis of liver biopsies from the Phase 2 FALCON1 trial of pegbelfermine. It demonstrates the sensitivity of FibroNest’s method to detect treatment and dose effects, with performance that compares imaging-based measurements (in partnership with Bristol Myers Squibb).
A third abstract discusses the performance of new FibroNest computational methods for the continuous histological quantification of bloat and inflammation in liver biopsies and the associated correlations with NASH-CRN histological grades.
Another summary in collaboration with the University of Oxford uses FibroNest to develop an etiology-independent composite score for automated histological assessment of fibrosis in liver biopsies.
Finally, several abstracts underline the interest of FibroNest to quantify the histological phenotype of fibrosis within the framework of in-vitro tests for medium throughput screening of antifibrotic compounds (in partnership with InSphero SA) and validation of the lead antifibrotic drug candidate in rodent models (in collaboration with Department of Therapeutic Discovery at Mount Sinai) with superior performance to all alternative methods, when they exist.
Specific details of these abstracts are available on the PharmaNest website at fibronest.com/science.
Dr Li Chen
Principal Investigator Contact Information
Image 1: FibroNest augmented pathology from a NASH biopsy
FibroNest generates augmented pathology images to visualize and quantify histological features of NASH
This content was posted through the press release distribution service on Newswire.com.
FibroNest augmented pathology from a NASH biopsy